| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/08/2004 | WO2004002433A1 Synergistic interaction of abacavir and alovudine |
| 01/08/2004 | WO2004002430A2 Combinations for the treatment of fungal infections |
| 01/08/2004 | WO2004002429A2 Methods of inhibiting pin1-associated states using a fredericamycin a compound |
| 01/08/2004 | WO2004002423A2 Cartilage enhancing food supplements with sucralose and methods of preparing the same |
| 01/08/2004 | WO2004002422A2 2’-c-methyl-3’-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections |
| 01/08/2004 | WO2004002421A2 Method for the treatment of multiple sclerosis |
| 01/08/2004 | WO2004002420A2 Oxime and/or hydrazone containing nitrosated and/or nitrosylated cyclooxigenase-2 selective inhibitors, compositions and methods of use |
| 01/08/2004 | WO2004002419A2 Carvedilol phosphate salts and/or solvates thereof, correspondinq compositions, and/or methods of treatment |
| 01/08/2004 | WO2004002418A2 Compositions and methods comprising protein activated receptor antagonists |
| 01/08/2004 | WO2004002416A2 Methods and materials for treating human papillomavirus infections |
| 01/08/2004 | WO2004002414A2 Self-emulsifying formulations of fenofibrate and/or fenofibrate derivatives with improved oral bioavailability and/or reduced food effect |
| 01/08/2004 | WO2004002410A2 2,4-disubstituted-pyridine n-oxides useful as hiv reverse transcriptase inhibitors |
| 01/08/2004 | WO2004002409A2 Cyclooxygenase-2 selective inhibitors, compositions and methods of use |
| 01/08/2004 | WO2004002406A2 Bicyclic pyrimidinones as coagulation cascade inhibitors |
| 01/08/2004 | WO2004002403A2 Sterols bearing pendant allosteric effectors of hemoglobin, and uses thereof |
| 01/08/2004 | WO2004002402A2 Administration of acetylcholinesterase inhibitors to the cerebral spinal fluid |
| 01/08/2004 | WO2004002401A2 Caspase inhibitors for the treatment of diseases and conditions caused by exposure to radionuclides, biological agents, or chemical agents |
| 01/08/2004 | WO2004002399A2 Use of gaba-c receptor antagonists for the treatment of myopia |
| 01/08/2004 | WO2004002398A2 Spherical pellet containing a water-soluble active ingredient |
| 01/08/2004 | WO2004002367A1 Drug eluting stent |
| 01/08/2004 | WO2004002296A2 Therapeutic methods for reducing fat deposition and treating associated conditions |
| 01/08/2004 | WO2004002226A1 Modulators of cdk9 as a therapeutic target in cardiac hypertrophy |
| 01/08/2004 | WO2003096874A3 Coated sustained release tablets of a hygroscopic compound for once-a-day therapy |
| 01/08/2004 | WO2003092647A3 Transport system in biological systems |
| 01/08/2004 | WO2003092606A3 Cholinesterase inhibitors to prevent injuries caused by chemicals |
| 01/08/2004 | WO2003090912A9 Pyrrolo-triazine aniline compounds useful as kinase inhibitors |
| 01/08/2004 | WO2003090693A3 Pharmaceutical composition containing lamotrigine particles of defined morphology |
| 01/08/2004 | WO2003090665A3 Regulation of erythrocyte apoptosis |
| 01/08/2004 | WO2003088880A3 Condom |
| 01/08/2004 | WO2003087174A3 Carbocyclic and oxacarbocyclic fumaric acid oligomers |
| 01/08/2004 | WO2003087088A3 (condensed) pyrimidone and (condensed) pyridone compounds, processes for their preparation, and pharmaceutical compositions containing them |
| 01/08/2004 | WO2003087035A8 2,5-bis-diamine-'1,4! benzoquinone derivatives for the treatment of alzheimer's disease a process for their preparation and intermediates therefor |
| 01/08/2004 | WO2003086315A3 Tyrosine kinase inhibitors |
| 01/08/2004 | WO2003086279A3 Inhibitors of akt activity |
| 01/08/2004 | WO2003085127A3 Method for identification of insulin receptor kinase activators |
| 01/08/2004 | WO2003085090A3 A human ribonucleotide reductase m2 subunit |
| 01/08/2004 | WO2003084928A8 Alpha, omega-dicarboximide derivatives as useful uro-selective α1α adrenoceptor blockers |
| 01/08/2004 | WO2003082241A3 Clarithromycin formulations having improved bioavailability |
| 01/08/2004 | WO2003080103A8 Antagonists of megalin or cubilin for use in preventing organ damage induced by therapeutic agents |
| 01/08/2004 | WO2003080032A3 Pharmaceutical formulation for the active ingredient budesonide |
| 01/08/2004 | WO2003078959A3 Methods for shp1 mediated neuroprotection |
| 01/08/2004 | WO2003077845A3 Compositions and methods for treating glaucoma and ocular hypertension |
| 01/08/2004 | WO2003077828A3 Novel florfenicol-type antibiotics |
| 01/08/2004 | WO2003076445A3 Microtubule stabilizing compounds |
| 01/08/2004 | WO2003076429A3 Azepane derivatives and their use as atk1 inhibitors |
| 01/08/2004 | WO2003075850A3 Methods for alzheimer's disease treatment and cognitive enhancement |
| 01/08/2004 | WO2003075842A3 Stable formulations of angiotensin converting enzyme (ace) inhibitors |
| 01/08/2004 | WO2003074732A3 Methods based on hormone dependency of primary cancer cells |
| 01/08/2004 | WO2003074059A3 Materials and methods relating to the treatment of lymphoma |
| 01/08/2004 | WO2003070166A3 Novel tyloindicines and related processes, pharmaceutical compositions and methods |
| 01/08/2004 | WO2003066205A3 Microcapsules having high carotenoid content |
| 01/08/2004 | WO2003064378A3 Novel compounds that inhibit factor xa activity |
| 01/08/2004 | WO2003062149A3 Antimicrobial composition including a triamine and a biocide |
| 01/08/2004 | WO2003061604A3 Novel alkyl/aryl hydroxy or keto thiepines. |
| 01/08/2004 | WO2003057151A3 A stable pharmaceutical formulation of paroxetine hydrochloride anhydrous and a process for preparation thereof |
| 01/08/2004 | WO2003045965A3 Compositions of nucleic acids and cationic aminoglycosides and methods of using and preparing the same |
| 01/08/2004 | WO2003030899A3 Use of 2-oxo-1-pyrrolidine derivatives for the treatment of dyskinesia and movement disorders |
| 01/08/2004 | WO2003030819A3 Tetracycline derivatives and methods of use thereof |
| 01/08/2004 | WO2003022224A3 Cox-2 function and wound healing |
| 01/08/2004 | WO2003020876A3 Polynucleotides encoding antigenic hiv type b polypeptides, polypeptides and uses thereof |
| 01/08/2004 | WO2003020257A3 USE OF β-ADRENOCEPTOR AGONISTS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES |
| 01/08/2004 | WO2003007923A3 Use of trifluoroacetyl alkyl-substituted phenyl derivatives, phenol derivatives, and benzoyl derivatives in the treatment and/or prophylaxis of obesity and accompanying diseases and/or secondary diseases |
| 01/08/2004 | WO2003007800A3 Methods for diagnosing and treating diseases and conditions of the digestive system and cancer |
| 01/08/2004 | WO2002099036A3 Inhibition of neurodegeneration |
| 01/08/2004 | WO2002092075A3 Therapeutic delivery of carbon monoxide |
| 01/08/2004 | WO2002080952A3 Therapeutic use and identification of modulators of a hedgehog signalling pathway or one of its target pathways |
| 01/08/2004 | WO2002078624A3 Aerosol administration of interleukin-2 liposomes |
| 01/08/2004 | WO2002059124A3 Substituted pyrroloquinolines and pyridoquinolines as serotonin agonists and antagonists |
| 01/08/2004 | WO2002056864A3 Differential delivery of nitric oxide |
| 01/08/2004 | WO2002056745A3 Method of treating parkinson's disease |
| 01/08/2004 | WO2002053522A3 Novel estrogen receptor ligands and methods i |
| 01/08/2004 | WO2002045737A3 Methods of treatment involving human mda-7 |
| 01/08/2004 | WO2002036202A3 Methods and compositions for the improvement of insulin sensitivity, reduction of hyperglycemia, and reduction of hypercholesterolemia with chromium complexes and alpha lipoic acid |
| 01/08/2004 | WO2001079524A3 Tissue-specific and pathogen-specific toxic agents, ribozymes, dnazymes and antisense oligonucleotides, and methods of use thereof |
| 01/08/2004 | WO2001066123A3 Composition consisting of phy906 and chemotherapeutic agents |
| 01/08/2004 | WO1999040955A3 Pressure sensitive adhesive matrix patch for the treatment of onychomycosis |
| 01/08/2004 | US20040006245 For therapy of cancer, restenosis, psoriasis, autoimmune disease, atherosclerosis, osteoarthritis, rheumatoid arthritis, heart failure, chronic pain, and neuropathic pain |
| 01/08/2004 | US20040006242 Immunomodulatory compounds and method of use thereof |
| 01/08/2004 | US20040006241 For use in female birth control, for therapy of hormone-dependent gynecological disorders and for hormone replacement therapy |
| 01/08/2004 | US20040006237 Amorphous and crystalline forms of losartan potassium and process for their preparation |
| 01/08/2004 | US20040006236 Diaminopropionic acid derivatives |
| 01/08/2004 | US20040006227 Polycyclic aryl and heteroaryl substituted 4-pyrones useful for selective inhibition of the coagulation cascade |
| 01/08/2004 | US20040006224 Synthesis of 2-alkyl amino acids |
| 01/08/2004 | US20040006143 Aminoalcohol derivatives |
| 01/08/2004 | US20040006142 Ocular tension depressor |
| 01/08/2004 | US20040006141 Amidocarboxylic acid compounds |
| 01/08/2004 | US20040006140 Controlled release arginine formulations |
| 01/08/2004 | US20040006139 As a food additive, as an animal food additive, as dietary substances, for improving general performances in the fields of sport, strength and endurance areas and, in deficiencies and illnesses of the central and/or peripheral nervous system |
| 01/08/2004 | US20040006138 For therapy of chronic myeloid leukemia where Bcr-Abl kinase is constitutively expressed in animals and humans |
| 01/08/2004 | US20040006136 Anthelmintics for preventing parasitic infections in human and animals |
| 01/08/2004 | US20040006135 Combination treatment for depression and anxiety |
| 01/08/2004 | US20040006134 Antiandrogenic biphenyls |
| 01/08/2004 | US20040006133 Oxime and/or hydrozone containing nitrosated and/or nitrosylated cyclooxygenase-2 selective inhibitors, compositions and methods of use |
| 01/08/2004 | US20040006132 For therapy |
| 01/08/2004 | US20040006129 Administering compound selected from 4,4'-(isopropylidenedithio) bis(2,6-di-tert-butylphenol), 2,3-Dihydro-5-hydroxy-2 2-dipentyl-4,6-di-tert-butyl-benzofuran, vitamin E and vitamin c |
| 01/08/2004 | US20040006128 Pharmaceutical compositions for lowering blood glucose and blood cholesterol levels |
| 01/08/2004 | US20040006127 Activation of the cystic fibrosis transmembrane conductance regulator chloride channel |
| 01/08/2004 | US20040006125 Bone growth compositions and methods |
| 01/08/2004 | US20040006124 Administering compound that is a ryanodine receptor antagonist in pharmaceutically acceptable vehicle to inhibit or prevent nerve cell injury or death |
| 01/08/2004 | US20040006123 Interleukin-4 gene expression inhibitors |